WallStSmart

MercadoLibre Inc. (MELI)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 56% more annual revenue ($45.20B vs $28.89B). TMO leads profitability with a 15.1% profit margin vs 6.9%. MELI appears more attractively valued with a PEG of 1.14. TMO earns a higher WallStSmart Score of 62/100 (C+).

MELI

Buy

60

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 6.7Quality: 5.3
Piotroski: 2/9Altman Z: 2.04

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 5.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MELIUndervalued (+59.3%)

Margin of Safety

+59.3%

Fair Value

$4955.41

Current Price

$1632.52

$3322.89 discount

UndervaluedFair: $4955.41Overvalued
TMOSignificantly Overvalued (-16.1%)

Margin of Safety

-16.1%

Fair Value

$408.60

Current Price

$465.00

$56.40 premium

UndervaluedFair: $408.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MELI4 strengths · Avg: 9.3/10
Return on EquityProfitability
36.0%10/10

Every $100 of equity generates 36 in profit

Revenue GrowthGrowth
44.6%10/10

Revenue surging 44.6% year-over-year

Market CapQuality
$94.80B9/10

Large-cap with strong market position

Free Cash FlowQuality
$4.78B8/10

Generating 4.8B in free cash flow

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$176.32B9/10

Large-cap with strong market position

Areas to Watch

MELI4 concerns · Avg: 3.0/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
47.4x2/10

Premium valuation, high expectations priced in

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
26.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MELI

The strongest argument for MELI centers on Return on Equity, Revenue Growth, Market Cap. Revenue growth of 44.6% demonstrates continued momentum. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : MELI

The primary concerns for MELI are Price/Book, Profit Margin, Piotroski F-Score. A P/E of 47.4x leaves little room for execution misses.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

MELI profiles as a hypergrowth stock while TMO is a mature play — different risk/reward profiles.

MELI carries more volatility with a beta of 1.41 — expect wider price swings.

MELI is growing revenue faster at 44.6% — sustainability is the question.

MELI generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 60/100), backed by strong 15.1% margins. MELI offers better value entry with a 59.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MercadoLibre Inc.

CONSUMER CYCLICAL · INTERNET RETAIL · USA

MercadoLibre, Inc. operates online trading platforms in Latin America. The company is headquartered in Buenos Aires, Argentina.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?